Torrent aims to be among first cos to launch Wegovy, Ozempic generics in Brazil
Semaglutide, the GLP-1 (glucagon-like peptide-1) compound which is sold under brand names Wegovy and Ozempic, is set to go off patent in key markets, including India and Brazil, in March 2026. Indian generic players are gearing up to cash in on the blockbuster opportunity.
While declining to share the company's specific plans, Sanjay Gupta, Torrent Pharma's head of international business, told investors in a post-earnings call that the Ahmedabad-based drugmaker is planning generic launches for both Ozempic and Wegovy in Brazil.
'...we are working on both the products without giving you more specificities. And we are trying to be in the wave-one of launches," Gupta said.
Also Read: India-UK FTA to boost bilateral trade for pharma, medtech
In Brazil, Ozempic's market size has declined since 2024 following the launch of Wegovy, said Gupta. 'The current size of Ozempic has come down a lot…by the time it goes off-patent, it would be smaller," he said, adding that due to changes in regulations, it is losing share to Wegovy.
'Wegovy should come to the market a little later because people have not started filing yet…I would be much more gung-ho about Wegovy because of where the market is going and the fact that we have better chances of being on day one," he said.
As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for GLP-1 is expected to grow to $100 billion by 2030, according to Goldman Sachs, a bank.
India, Brazil drive growth
Torrent Pharma reported a 20% year-on-year increase in net profit in the June quarter to ₹548 crore, on the back of double-digit growth in its largest branded markets, India and Brazil.
The company's revenue rose 11% year-on-year to ₹3,178 crore in the June quarter, in line with estimates. Its Ebitda (earnings before interest, taxes, depreciation, and amortisation) increased 14% to ₹1,032 crore, with an operating Ebitda margin of 32.5%.
The company's management expects the margin to remain stable through FY26.
Its India business grew 11% YoY to ₹1,811 crore, led by outperformance in key therapies.
Also Read: Cipla sees weight-loss drugs as the biggest opportunity in India
'We expect the India business to continue outperforming the market growth. Our focus during the year will be to continue to improve the market share in focus therapies, new launch performance, improve teamforce productivity in expanded divisions and regions and continue the investments and scale-up of the consumer health portfolios," Aman Mehta, managing director-designate, told investors.
Mehta is set to take the role of managing director at Torrent Pharmaceuticals starting 1 August. He has been involved mainly with Torrent Pharma's India business, the company's largest revenue contributor, and has played an instrumental role in the integration of Unichem Laboratories Ltd, acquired in 2017, and the acquistion of Curatio Healthcare Pvt. Ltd. in 2022.
The company's Brazil business saw its revenues rise 11% to ₹218 crore.
JB Pharma acquisition to boost India play
Torrent is currently in the process of acquiring a controlling stake in drugmaker JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR. The deal, announced in late June, values JB Chemicals at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities.
Also Read: Contract drug makers timed their IPOs right. But are they worth the premium?
The deal will strengthen Torrent's presence in the Indian market, catapulting it to the fifth-largest pharma company in the country, from seventh position. It will also facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment.
The company is currently awaiting a decision from the Competition Commission of India (CCI) on the deal, the management said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
11 minutes ago
- The Hindu
RSS arm seeks clarity on draft guidelines on biosimilars
Swadeshi Jagran Manch (SJM), economic wing of the Rashtriya Swayamsewak Sangh (RSS), urged the Central Drugs Standard Control Organisation (CDSCO), the apex drug regulatory authority, to bring more clarity in its draft guidelines to ensure production of high-quality and cost-effective biosimilars in the country. In a letter to the Director General of CDSCO, SJM sought safeguards for the Indian industry from 'international pressures for regulations' that favour multi-national pharma companies. The CDSCO had recently issued the 2025 draft guidelines on similar biologics, also called biosimilars. 'Though the draft guidelines represent a pivotal advancement in making affordable, life-saving biosimilars accessible to millions of Indians suffering from chronic and life-threatening conditions such as cancer, diabetes, and autoimmune disorders it requires more clarity and direction,' the SJM letter reads. The SJM appreciated the draft guidelines for embracing the '3Rs principle' (replacement, reduction, refinement) as it reflects India's commitment to ethical scientific practices and alignment with global standards for animal welfare. Modern technologies, including in-vitro assays, organ-on-chip models, and computational simulations, provide robust, accurate, and humane alternatives to confirm the safety and biosimilarity of these drugs, it said. 'These methods are often faster and more precise than animal studies, reducing both ethical concerns and development costs,' it added. The organisation, however, noted that the guidelines stipulating that it will be the discretion of the CDSCO to decide whether a requirement of 'additional non-clinical in vivo animal studies' should be waived or not, poses a 'risk' of increasing biosimilar development cost. This provision goes against the practices of the leading regulatory authorities in other countries, it added. 'Prominent regulatory authorities like the UK MHRA, European Medicine Agency (EMA) Health Canada, and USFDA have either eliminated or phased out mandatory animal testing for biosimilars,' SJM said, adding its recommendation that waiving animal studies entirely when comprehensive laboratory tests demonstrate high similarity between a biosimilar and its reference product. Recently, civil societies, in a letter to CDSCO on the draft guidelines on biosimilars, has urged that there is an urgent need to eliminate unnecessary animal studies, and establish clear conditions for requiring comparative clinical trials for affordable biosimilars without compromising safety and efficacy. According to the SJM, the draft guidelines' provision to waive certain clinical trials when biosimilarity is established through analytical and functional studies is a forward-thinking measure, saying this approach can significantly reduce development costs and expedite market entry, which is critical for patients awaiting affordable treatments. However, the lack of explicit criteria in the guidelines for when waivers are permitted introduces ambiguity, potentially leading to inconsistent application and delays as well as 'room for corrupt practices', it said, stressing the need to establish 'clear conditions' for conduct of clinical trials.
Time of India
25 minutes ago
- Time of India
India-US trade: Officials react cautiously to Russia penalty threat
NEW DELHI: As President Trump threatened to impose a penalty on India for its trade ties with Russia, Indian officials reacted cautiously as they reiterated India's position that securing energy needs of the Indian people is the overriding priority. A source, speaking on condition of anonymity, said India is buying oil not because it wants to help Moscow but because it's the right thing to do based on the prevailing market conditions and the global geopolitical situation. Trump said India has always bought "a vast majority of their military equipment from Russia, and are Russia's largest buyer of energy along with China". However, India had been keen on announcing new plans for defence procurement and co-production arrangements with the US too. During PM Narendra Modi's visit to the US in Feb, Trump pushed India to lower tariffs and buy more defence products from the US that would facilitate a fair trade deal. With the US encouraging India to reduce its dependence on Russian-origin equipment, the leaders had agreed to expand defence sales and co-production to strengthen interoperability and defence industrial cooperation. In that context, govt sources here said some of Trump's claims don't stand up to scrutiny. "The fact is that India-US defence trade has been increasing since 2008, while the dependence on Russia continues to reduce considerably," said an official on condition of anonymity, adding that the US is now among the top arms suppliers to India along with Russia and France. While much has been made of India's imports from Russia, little attention has been paid to the fact that its crude imports from the US have seen a significant jump too with the US emerging as the 4th largest supplier to India in April this year, according to Indian officials. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
Time of India
39 minutes ago
- Time of India
Trump's rant against India undercuts claim of having used trade to broker Operation Sindoor truce with Pakistan
NEW DELHI: When he lashed out at India for not lowering tariffs for American businesses, US President Donald Trump undercut the claim he has incessantly made: that on May 10, the Modi govt caved in to his threat of not doing trade with India if it did not pause Operation Sindoor against Pakistan. He had also suggested that India would get a good deal for its compliance. Trump's outburst on Truth Social on Wednesday conflicted with his claim of having frog marched India to cease Operation Sindoor by dangling the threat of stopping trade. Interestingly, the 'all things not good' admission from the US president, who has earned the reputation of being the global scold because of his petulance and pugnacity, came on a day when the two Houses of Parliament concluded a debate on Operation Sindoor that was dominated by Trump's claim of having mediated the suspension of hostilities. On Tuesday, PM Modi had refuted Trump's claim, saying no global leader had asked him to cease the offensive, and that it was the sheer ferocity of the IAF strikes on Pakistan's airbases that led Islamabad to sue for peace on May 10. That was getting as close as an Indian PM could get to accuse the US president of inexactitude. External affairs minister S Jaishankar went a step further on both Tuesday and Wednesday, stating that Trump and Modi did not talk between April 22 and June 16 when in a telephonic conversation, Modi had rebutted the suggestion that the operation against Pakistan was ceased because of anyone's mediation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Modern manufacturing techniques explained. Shopper Experts Learn More Undo In a significant decision, the Modi govt got foreign secretary Vikram Misri to let out details of the conversation. India has also consistently rebutted Trump's claim that trade was a factor in India's decision to stop attacking Pakistan after May 10.
